Exact Mass: 451.178349

Exact Mass Matches: 451.178349

Found 500 metabolites which its exact mass value is equals to given mass value 451.178349, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Doxazosin

1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine

C23H25N5O5 (451.18556)

Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α₁-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α₁-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Piscerythramine

4-Amino-5,7,3-trihydroxy-5-methoxy-2,6-diprenylisoflavone

C26H29NO6 (451.19947740000003)

A hydroxyisoflavone that is isoflavone substituted by hydroxy groups at positions 5, 7 and 3, prenyl groups at positions 2 and 6, a methoxy group at position 5 and an amino group at position 4.

Flucythrinate

Benzeneacetic acid,4-(difluoromethoxy)-a-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester

C26H23F2NO4 (451.1595062)

5-O-Feruloylnigrumin

(2Z)-2-cyano-2-(2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethylidene)ethyl (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C21H25NO10 (451.147839)

5-O-Feruloylnigrumin is found in fruits. 5-O-Feruloylnigrumin is a constituent of the seeds of Ribes nigrum (blackcurrant). Constituent of the seeds of Ribes nigrum (blackcurrant). 5-O-Feruloylnigrumin is found in fruits.

1-Hydroxytrimazosin

2-Hydroxy-2-hydroxymethylpropyl-4(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazine carboxylic acid

C20H29N5O7 (451.2066884)

4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide

4-Amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-hydroxybenzene-1-carboximidate

C22H27ClFN3O4 (451.16740240000007)

4-Hydroxypropranolol glucuronide

3,4,5-trihydroxy-6-[(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}naphthalen-1-yl)oxy]oxane-2-carboxylic acid

C22H29NO9 (451.18422240000007)

Succinyl-trialanine-4-nitroanilide

3-[(1-{[1-({1-[(4-nitrophenyl)carbamoyl]ethyl}-C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}ethyl)-C-hydroxycarbonimidoyl]propanoate

C19H25N5O8 (451.170305)

(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid

2-{[3-({[4-(4-fluorophenoxy)phenyl]methyl}-C-hydroxycarbonimidoyl)-4-methoxyphenyl]methyl}butanoate

C26H26FNO5 (451.17949180000005)

tetrahydrogeranylgeranyl-PP

3,7,11,15-Tetramethylhexadeca-2,14-dien-1-yl (phosphonatooxy)phosphonic acid

C20H37O7P2 (451.2014412)

Tetrahydrogeranylgeranyl-pp is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Tetrahydrogeranylgeranyl-pp can be found in a number of food items such as muskmelon, wax gourd, deerberry, and pineapple, which makes tetrahydrogeranylgeranyl-pp a potential biomarker for the consumption of these food products.

Isopiscerythramine

4-Amino-5,7,3-trihydroxy-5-methoxy-8,2-diprenylisoflavone

C26H29NO6 (451.19947740000003)

Pseudolycorine-1-O-beta-D-glucoside

C22H29NO9 (451.18422240000007)

O-Methylsakerinol A

C23H33NO6S (451.2028478000001)

dysidine

C23H33NO6S (451.2028478000001)

A sesquiterpenoid isolated from the sponge Dysidea sp. that is 5-amino-2-hydroxy-3-methyl-1,4-benzoquinone in which one of the hydrogens of the methyl group is replaced by a 1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-2-yl group and one of the hydrogens attached to the nitrogen is replaced by a 2-sulfoethyl group. Dysidine selectively inhibits human synovial phospholipase A2 (EC 3.1.1.4) with an IC50 = 2.0 muM.

C27H21N3O4

C27H21N3O4 (451.15319860000005)

(E)-3-(methylsulfonyl)-propenoic acid (2E,6E)-4-(8-hydroxy-3,7-dimethyl-2,6-octadienyloxy)-3-methoxyphenethyl amide|O-methylsakerinol A

C23H33NO6S (451.2028478000001)

Uvarindole D

C29H25NO4 (451.178349)

SCHEMBL21397092

C23H33NO6S (451.2028478000001)

9beta,2-dihydroxy-4,5-dimethoxy-lythran-12-one|9beta-hydroxyvertine

C26H29NO6 (451.19947740000003)

(1S,4R)-1-(beta-D-Glucopyranosyloxy)-4-(6-deoxy-beta-D-gulopyranosyloxy)-2-cyclopentene-1-carboxamide

C18H29NO12 (451.16896740000004)

doxazosin

Doxazosin, (R)-

C23H25N5O5 (451.18556)

C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3293

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.18490840000004)

C17H25N9O6 (451.192771)

Ethanone, 1-(4-(4-chloro-3-methoxyphenyl)-1-piperazinyl)-2-(3-(1H-imidazol-2-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)-

C22H22ClN7O2 (451.1523422)

(1r)-1-[(4-{[(6,7-Dihydro[1,4]dioxino[2,3-C]pyridazin-3-Yl)methyl]amino}piperidin-1-Yl)methyl]-9-Fluoro-1,2-Dihydro-4h-Pyrrolo[3,2,1-Ij]quinolin-4-One

C24H26FN5O3 (451.20195780000006)

Dihydrocodeine bitartrate

C22H29NO9 (451.18422240000007)

D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

Piritrexim isethionate

C19H25N5O6S (451.152547)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor

cyano(3-phenoxyphenyl)methyl (2S)-2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate

C26H23F2NO4 (451.1595062)

Ftorpropazine

C22H24F3N3O2S (451.154124)

C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

Homofenazine

C23H28F3N3OS (451.19050740000006)

C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

N-[2,6-dimethyl-3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N,4-dimethylbenzenesulfonamide

C21H29N3O4S2 (451.15993940000004)

2-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-D]pyrimidin-5-YL)-ethyl]-benzoylamino}-4-(2H-tetrazol-5-YL)-butyric acid

C20H21N9O4 (451.17164260000004)

2-[[5-[(1,2,4a,5-Tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl)methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]ethanesulfonic acid

C23H33NO6S (451.2028478000001)

4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide

4-Amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-hydroxybenzene-1-carboximidate

C22H27ClFN3O4 (451.16740240000007)

(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid

2-{[3-({[4-(4-fluorophenoxy)phenyl]methyl}-C-hydroxycarbonimidoyl)-4-methoxyphenyl]methyl}butanoate

C26H26FNO5 (451.17949180000005)

tetrahydrogeranylgeranyl-PP

C20H37O7P2-3 (451.2014412)

[oxido-[(2E)-3,7,11,15-tetramethylhexadeca-2,14-dienoxy]phosphoryl] phosphate

C20H37O7P2-3 (451.2014412)

Suc-DL-Ala-DL-Ala-DL-Ala-pNA

C19H25N5O8 (451.170305)

7-{2-Hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione

C23H25N5O5 (451.18556)

N-[[2-(diethylamino)ethylamino]-sulfanylidenemethyl]-3-(4-methoxyphenyl)-1-phenyl-4-pyrazolecarboxamide

C24H29N5O2S (451.20418540000003)

10-(3-Carboxypropyl)-3,6-bis(dimethylamino)acridinium perchlorate

C21H26ClN3O6 (451.1510046000001)

ethyl 4-{[(2E)-2-(3-methylbenzylidene)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl]carbonyl}piperazine-1-carboxylate

C24H25N3O4S (451.15656900000005)

1-[(8R,9R,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[3-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C23H28F3N3O3 (451.2082654000001)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

3-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide

C21H26FN3O5S (451.1577118000001)

2-[(2R,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

2-[(2S,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

2-[(2S,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)oxan-2-yl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

N-[(2S,3R,6S)-6-[2-[(3-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(2-pyridinyl)acetamide

C21H26FN3O5S (451.1577118000001)

1-[(8R,9S,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

1-[(8S,9R,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

1-[(8S,9S,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide

C20H29N5O5S (451.18893040000006)

2-[(2S,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

2-[(2R,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

2-[(2S,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

2-[(2R,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

2-[(2R,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide

C21H26FN3O5S (451.1577118000001)

N-[(2R,3S,6R)-6-[2-[(3-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(2-pyridinyl)acetamide

C21H26FN3O5S (451.1577118000001)

N-[(2S,3R,6R)-6-[2-[(3-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(2-pyridinyl)acetamide

C21H26FN3O5S (451.1577118000001)

1-[(8S,9R,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

1-[(8S,9S,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

1-[(8R,9R,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

1-[(8R,9S,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone

C21H30BrN3O3 (451.14704100000006)

Lysidine monophosphate

C15H26N5O9P (451.14680760000005)

A pyrimidine ribonucleoside 5-monophosphate that is CMP in which the 2-keto group on the cytosine ring is replaced by an epsilon-L-lysyl residue.

(5Z)-5-[(1-Benzyl-3,4-dihydro-2H-quinolin-6-yl)methylidene]-1-(2-methylphenyl)-1,3-diazinane-2,4,6-trione

C28H25N3O3 (451.189582)

Flucythrinate

Benzeneacetic acid,4-(difluoromethoxy)-a-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester

C26H23F2NO4 (451.1595062)

4-[[2-[(3-methylphenyl)methylidene]-3-oxo-4H-1,4-benzothiazin-6-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester

C24H25N3O4S (451.15656900000005)

LPS 12:3;O

C18H30NO10P (451.160725)

ST 20:4;O7;Gly

C22H29NO9 (451.18422240000007)

ST 20:5;O4;Tau

C22H29NO7S (451.16646440000005)

ST 21:4;O3;Tau

C23H33NO6S (451.2028478000001)

AZ304

C27H25N5O2 (451.200815)

AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity[1].

PRGL493

(2s,3s,6r)-16-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-one

(2s,3s,6r)-16-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-one

C27H21N3O4 (451.15319860000005)

16-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-one

16-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-one

C27H21N3O4 (451.15319860000005)

(2s,3r,6r)-16-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-one

(2s,3r,6r)-16-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-one

C27H21N3O4 (451.15319860000005)

(2e)-2-cyano-2-(2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethylidene)ethyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C21H25NO10 (451.147839)

(1s,2s,3e,4s,6r)-3-(cyanomethylidene)-2,6-dihydroxy-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl benzoate

C21H25NO10 (451.147839)

(1s,2r,3s,4z,5r)-4-(cyanomethylidene)-2,3-dihydroxy-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl benzoate

C21H25NO10 (451.147839)

2-[(5-{[(2r,4s,4as,8as)-2,4,8,8a-tetramethyl-1,3,4,4a,5,6-hexahydronaphthalen-2-yl]methyl}-4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)amino]ethanesulfonic acid

C23H33NO6S (451.2028478000001)

3-(cyanomethylidene)-2,6-dihydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl benzoate

C21H25NO10 (451.147839)